English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 18076/20274 (89%)
造訪人次 : 5356616      線上人數 : 1288
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧:
  • 您可在西文檢索詞彙前後加上"雙引號",以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋,建議至進階搜尋限定作者欄位,可獲得較完整資料
  • 進階搜尋
    請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/31038


    標題: Overexpression of the PSAT1 Gene in Nasopharyngeal Carcinoma Is an Indicator of Poor Prognosis
    作者: Liao, Kuang-Ming
    Chao, Tung-Bo
    Tian, Yu-Feng
    Lin, Ching-Yih
    Lee, Sung-Wei
    Chuang, Hua-Ying
    Chan, Ti-Chun
    Chen, Tzu-Ju
    Hsing, Chung-Hsi
    Sheu, Ming-Jen
    Li, Chien-Feng
    貢獻者: Chi Mei Med Ctr, Dept Internal Med
    Yuans Gen Hosp, Dept Colorectal Surg
    Meiho Univ, Dept Hlth Business Adm
    Chi Mei Med Ctr, Div Gen Surg
    Chia Nan Univ Pharm & Sci, Dept Hlth & Nutr
    Chi Mei Med Ctr, Dept Internal Med
    Southern Taiwan Univ Sci & Technol, Dept Leisure Recreat & Tourism Management
    Chi Mei Med Ctr, Dept Radiat Oncol
    Chi Mei Med Ctr, Dept Pathol
    Chi Mei Med Ctr, Dept Anesthesiol
    Natl Hlth Res Inst, Natl Inst Canc Res
    Southern Taiwan Univ Sci & Technol, Dept Biotechnol
    關鍵字: PSAT1
    Nasopharyngeal carcinoma
    prognosis
    trials
    日期: 2016
    上傳時間: 2018-01-18 11:40:22 (UTC+8)
    出版者: Ivyspring Int Publ
    摘要: Purpose: Nasopharyngeal carcinoma (NPC) is a common cancer in southern China and Southeast Asia, but risk stratification and treatment outcome in NPC patients remain suboptimal. Our study identified and validated metabolic drivers that are relevant to the pathogenesis of NPC using a published transcriptome. Phosphoserine aminotransferase 1 (PSAT1) is an enzyme that is involved in serine biosynthesis, and its overexpression is associated with colon cancer, non-small cell lung cancer and breast cancer. However, its expression has not been systemically evaluated in patients with NPC. Materials and Methods: We evaluated two public transcriptomes of NPC tissues and benign nasopharyngeal mucosal epithelial tissues that deposited in the NIH Gene Expression Omnibus database under accession number GSE34574 and GSE12452. We also performed immunohistochemical staining and assessment of PSAT1 in a total of 124 NPC patients received radiotherapy and were regularly followed-up until death or loss. The endpoints analyzed were local recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), disease-specific survival (DSS), and overall survival (OS). Results: We retrospectively evaluated 124 patients with NPC and found that high PSAT1 expression was associated with poor prognosis of NPC and indicator of advanced tumor stage. High PSAT1 expression also correlated with an aggressive clinical course, with significantly shorter DSS (HR=2.856, 95% CI 1.599 to 5.101), DMFS (HR=3.305, 95% CI 1.720 to 6.347), LRFS (HR=2.834, 95% CI 1.376 to 5.835), and OS HR=2.935, 95% CI 1.646-5.234) in multivariate analyses. Conclusions: Our study showed that PSAT1 is a potential prognostic biomarker and higher expression of PSAT1 is associated with a poor prognosis in NPC.
    關聯: Journal of Cancer, v.7 n.9, pp.1088-1094
    顯示於類別:[保健營養系(所) ] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    31038.pdf742KbAdobe PDF252檢視/開啟
    index.html0KbHTML1351檢視/開啟


    在CNU IR中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋